$15.26
-$0.23
(-1.48%)
Quote as of 3:59 PM EST on 02/10/12
MAP Pharmaceuticals
NASDAQ:MAPP
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Bank of NY Mellon cuts passive stake in MAP Pharmaceuticals to 9.44% from 10.07%
Play TheStreet's FDA Drug-Approval Contest
MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors
MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors
Canaccord Genuity Starts MAP Pharmaceuticals (MAPP) at Buy
MAP Pharmaceuticals initiated with a Buy at Canaccord
MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
MAPping Out New Form Of Old Drug
27 Hot Drugs Facing FDA Approval in 2012
JPMorgan Starts MAP Pharmaceuticals (MAPP) at Overweight
MAP Pharmaceuticals initiated with an Overweight at JP Morgan
Top 10 Undervalued Stocks With Large Cash Cushions
MAP Pharmaceuticals, Inc. (MAPP) to Ring The NASDAQ Stock Market Opening Bell
MAP Pharmaceuticals, Inc. (MAPP) to Ring The NASDAQ Stock Market Opening Bell
MAP Pharma posts 3Q profit on Levadex payments
MAP Pharma's LEVADEX NDA was filed in Q3 with PDUFA goal date March 26, 2012
MAP Pharmaceuticals reports Q3 EPS 35c vs. consensus 30c
MAP Pharmaceuticals Reports Third Quarter of 2011 Financial Results
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Allergan Reports Third Quarter 2011 Operating Results
Weekly CFO Sells Highlight: AXAS, MDW, MAPP, CATM, OVRL
MAP PHARMACEUTICALS, INC. (MAPP) CFO Christopher Y Chai sells 32,000 Shares
Summer Street's biotech analyst research team to hold a conference call
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
MAP Pharmaceuticals recent weakness a buying opportunity, says Wedbush
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® Headache and Migraine
MAP Pharma issued migraine treatment patent
MAP Pharma issued U.S. patent for methods of achieving rapid migraine relief
MAP Pharmaceuticals Appoints Frederick H. Graff Vice President, Commercial Operations
MAP Pharmaceuticals Receives FDA Acceptance for Filing of NDA for Levadex
MAP Pharmaceuticals reports Q2 EPS (28c) vs. consensus (38c)
MAP Pharmaceuticals, Inc. (MAPP) Tops Q2 EPS by 10c
MAP Pharmaceuticals Reports Second Quarter of 2011 Financial Results
MAP Pharmaceuticals, Inc. Gets $20 Million Payment from Allergan Inc. for FDA Filing
MAP Pharmaceuticals gets $20M payment for FDA filing
MAP Pharmaceuticals' LEVADEX accepted for filing by the FDA
